Clinical Trials List
2016-08-01 - 2020-12-31
Phase II
Terminated5
ICD-10C50
Malignant neoplasm of breast
ICD-10C79.81
Secondary malignant neoplasm of breast
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 林智一 Division of Others
- Chih-Jung Chen Division of General Surgery
- Liang-Chih Liu Division of General Surgery
- Yao-Chung Wu Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 金光亮 Division of General Surgery
- 林燕淑 Division of General Surgery
- Ta-Chung Chao Division of Hematology & Oncology
- Yi-Fang Tsai Division of General Surgery
- 邱仁輝 Division of General Surgery
- Chun-Yu Liu Division of Radiation Therapy
- 林永慧 Division of Radiology
The Actual Total Number of Participants Enrolled
1 Stop recruiting
Audit
None
Co-Principal Investigator
Audit
None
Co-Principal Investigator
- Wei-Hong Cheng Division of Hematology & Oncology
- Tsu-Yi Chao Division of Hematology & Oncology
- 蘇勇誠 Division of Hematology & Oncology
- Wei-Hwa Lee Division of Others -
- Yao-Yu Hsieh Division of Hematology & Oncology
- TSU-YI CHAO Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
4 Terminated
Audit
None
Taiwan National PI
Co-Principal Investigator
- 張潤忠 Division of General Surgery
- Wen-Chi Shen Division of General Surgery
- 沈士哲 Division of General Surgery
- Chi-Chang Yu Division of General Surgery
- Mengting Peng Division of General Surgery
- Yung-Chang Lin Division of General Surgery
The Actual Total Number of Participants Enrolled
12 Stop recruiting
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
225 participants
